Literature DB >> 717935

Spironolactone therapy for hirsutism in a hyperandrogenic woman.

K P Ober, J F Hennessy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 717935     DOI： 10.7326/0003-4819-89-5-643

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  9 in total

1.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 2.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

Review 3.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

4.  Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience.

Authors:  Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

5.  Spironolactone in the treatment of hirsutism.

Authors:  A Köksal; R Pabuçcu; C Akyürek
Journal:  Arch Gynecol       Date:  1987

6.  Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.

Authors:  D J Evans; C W Burke
Journal:  J R Soc Med       Date:  1986-08       Impact factor: 5.344

7.  Endocrine and clinical effects of spironolactone in female hyperandrogenism.

Authors:  R Siegberg; P Ylöstalo; T Laatikainen; R Pelkonen; U H Stenman
Journal:  Arch Gynecol       Date:  1987

8.  The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.

Authors:  M D Fernandez; G D Carter; T N Palmer
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

9.  Polycystic ovarian disease: endocrinological parameters with specific reference to growth hormone and somatomedin-C.

Authors:  W Urdl
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.